Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

7.545
-0.905-10.71%
Volume:4.17M
Turnover:32.11M
Market Cap:7.94B
PE:-20.39
High:8.455
Open:8.455
Low:7.395
Close:8.450
52wk High:19.860
52wk Low:7.395
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:2.89
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-28.59%
ROA:-19.64%
PB:2.99
PE(LYR):-20.39
PS:7159.24

Loading ...

Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million

Reuters
·
Aug 21

Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY

THOMSON REUTERS
·
Aug 21

Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others

THOMSON REUTERS
·
Aug 21

Ascletis Pharma (SEHK:1672) At 5x P B On Obesity Trial Momentum Looks About Right

Simply Wall St.
·
Aug 12

Ascletis Pharma Begins Obesity Drug Candidate Trial

MT Newswires Live
·
Aug 10

Ascletis Launches U.S. Phase I Trials for Potential First-in-Class Monthly Obesity Injections ASC36 and ASC36_35FDC

Bulletin Express
·
Aug 10

Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: Asc36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and Asc36_35Fdc Once-Monthly Injection, a Co-Formulation of Asc36 and Glp-1R/Gipr Peptide Agonist Asc35

THOMSON REUTERS
·
Aug 10

Ascletis-B Launches Two Phase 1 Obesity Studies in the United States

Stock News
·
Aug 10

Ascletis Pharma - U.S. FDA Clears Ind Applications for Asc36 and Asc36_35Fdc

THOMSON REUTERS
·
Aug 10

Ascletis Says FDA Clears INDs for Obesity Candidates Asc36, Asc36_35fdc

Reuters
·
Aug 10

Hong Kong Market Movers: Innovative Drug Stocks Rally as Earnings Season Approaches, Medical Conferences Expected to Provide Catalysts

Stock News
·
Aug 07

Ascletis Pharma Shares Surge 5% on Global Phase 3 Trial Launch for GLP-1 Oral Drug ASC30

Deep News
·
Aug 04

Is Ascletis’ Biologic Obesity Pipeline Altering The Investment Case For Ascletis Pharma (SEHK:1672)?

Simply Wall St.
·
Aug 04

Ascletis Announces Initiation of Global Phase Iii for Oral Small Molecule Glp-1, Asc30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule Glp-1/Gip/Amylin Fixed-Dose Combination

THOMSON REUTERS
·
Aug 03

Ascletis Pharma - Has Sufficient Cash to Support Operations into 2029

THOMSON REUTERS
·
Aug 03

Ascletis Pharma - Expects Asc30 Phase Iii Topline Data Q3 2028; Nda End 2028; Maa Early 2029

THOMSON REUTERS
·
Aug 03

Ascletis Pharma - Initiates Global Phase Iii for Asc30 in Obesity with 4,600 Participants

THOMSON REUTERS
·
Aug 03

Ascletis Says FDA Clears Phase III Trials for Oral GLP-1 Obesity Drug ASC30

Reuters
·
Aug 03

Ascletis Pharma Schedules Board Meeting to Review Interim Results, Consider Dividend

Reuters
·
Aug 03

Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jul 30